# The Effects of 12-months of Denosumab on Bone Density in Prevalent Kidney Transplant Recipients

> **NCT03960554** · PHASE2 · TERMINATED · sponsor: **Thomas Nickolas, MD MS** · enrollment: 8 (actual)

## Conditions studied

- Osteoporosis
- Renal Osteodystrophy
- Kidney Transplant; Complications

## Interventions

- **DRUG:** Denosumab Inj 60 mg/ml
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03960554
- **Lead sponsor:** Thomas Nickolas, MD MS
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-01-16
- **Primary completion:** 2021-12-02
- **Final completion:** 2021-12-02
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Study lost funding
- **Last updated:** 2024-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03960554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03960554, "The Effects of 12-months of Denosumab on Bone Density in Prevalent Kidney Transplant Recipients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03960554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*